Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRS NASDAQ:ARQT NASDAQ:CARA NASDAQ:STTK NASDAQ:TBPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$1.90-7.3%$1.89$1.05▼$5.17$222.08M0.261.09 million shs733,240 shsARQTArcutis Biotherapeutics$20.88-0.1%$17.63$8.03▼$21.84$2.51B2.062.05 million shs1.32 million shsCARACara Therapeutics$15.19$8.13▼$19.08$24.33M0.4122,224 shs237,144 shsSTTKShattuck Labs$1.81+0.6%$1.69$0.69▼$2.71$86.23M1.89415,563 shs292,449 shsTBPHTheravance Biopharma$14.26+1.6%$13.85$7.90▼$15.15$707.07M-0.03318,320 shs331,920 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics+6.22%+5.13%+11.41%+27.33%+76.72%ARQTArcutis Biotherapeutics-3.33%+0.97%+23.22%+42.54%+115.12%CARACara Therapeutics0.00%0.00%0.00%0.00%+67.30%STTKShattuck Labs+1.69%-18.18%-15.89%+122.44%+24.14%TBPHTheravance Biopharma+1.01%-3.24%+1.23%+24.80%+61.38%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$1.90-7.3%$1.89$1.05▼$5.17$222.08M0.261.09 million shs733,240 shsARQTArcutis Biotherapeutics$20.88-0.1%$17.63$8.03▼$21.84$2.51B2.062.05 million shs1.32 million shsCARACara Therapeutics$15.19$8.13▼$19.08$24.33M0.4122,224 shs237,144 shsSTTKShattuck Labs$1.81+0.6%$1.69$0.69▼$2.71$86.23M1.89415,563 shs292,449 shsTBPHTheravance Biopharma$14.26+1.6%$13.85$7.90▼$15.15$707.07M-0.03318,320 shs331,920 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics+6.22%+5.13%+11.41%+27.33%+76.72%ARQTArcutis Biotherapeutics-3.33%+0.97%+23.22%+42.54%+115.12%CARACara Therapeutics0.00%0.00%0.00%0.00%+67.30%STTKShattuck Labs+1.69%-18.18%-15.89%+122.44%+24.14%TBPHTheravance Biopharma+1.01%-3.24%+1.23%+24.80%+61.38%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics 2.90Moderate Buy$8.71358.65% UpsideARQTArcutis Biotherapeutics 2.63Moderate Buy$19.80-5.17% DownsideCARACara Therapeutics 0.00N/AN/AN/ASTTKShattuck Labs 2.50Moderate Buy$3.0065.75% UpsideTBPHTheravance Biopharma 3.00Buy$23.0061.29% UpsideCurrent Analyst Ratings BreakdownLatest ACRS, CARA, ARQT, TBPH, and STTK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025ACRSAclaris TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/14/2025ARQTArcutis BiotherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025STTKShattuck LabsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025TBPHTheravance BiopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)9/27/2025ACRSAclaris TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ARQTArcutis BiotherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025STTKShattuck LabsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025TBPHTheravance BiopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)9/15/2025TBPHTheravance BiopharmaZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/12/2025TBPHTheravance BiopharmaB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$28.009/11/2025TBPHTheravance BiopharmaB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 10/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$18.72M11.00N/AN/A$1.44 per share1.32ARQTArcutis Biotherapeutics$196.54M12.74N/AN/A$1.35 per share15.47CARACara Therapeutics$7.14M0.00N/AN/A$12.58 per share0.00STTKShattuck Labs$5.72M15.16N/AN/A$1.67 per share1.08TBPHTheravance Biopharma$64.38M11.15N/AN/A$3.57 per share3.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$132.07M-$1.37N/AN/AN/A-802.03%-34.01%-24.18%11/5/2025 (Estimated)ARQTArcutis Biotherapeutics-$140.04M-$0.75N/AN/AN/A-35.40%-62.62%-25.16%10/28/2025 (Estimated)CARACara Therapeutics-$118.51M-$21.01N/AN/AN/A-1,099.76%-367.97%-107.43%N/ASTTKShattuck Labs-$75.41M-$1.21N/AN/AN/AN/A-81.80%-71.46%11/13/2025 (Estimated)TBPHTheravance Biopharma-$56.42M$0.2459.4240.74N/A16.88%6.93%3.52%11/11/2025 (Estimated)Latest ACRS, CARA, ARQT, TBPH, and STTK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/13/2025Q3 2025STTKShattuck Labs-$0.15N/AN/AN/AN/AN/A11/11/2025Q3 2025TBPHTheravance Biopharma-$0.03N/AN/AN/A$19.89 millionN/A11/5/2025Q3 2025ACRSAclaris Therapeutics-$0.13N/AN/AN/A$1.59 millionN/A10/28/2025Q3 2025ARQTArcutis Biotherapeutics-$0.09N/AN/AN/A$86.69 millionN/A8/14/2025Q2 2025STTKShattuck Labs-$0.25-$0.24+$0.01-$0.24N/AN/A8/7/2025Q2 2025ACRSAclaris Therapeutics-$0.13-$0.13N/A-$0.13$1.34 million$1.78 million8/6/2025Q2 2025ARQTArcutis Biotherapeutics-$0.18-$0.13+$0.05-$0.13$72.70 million$81.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/AARQTArcutis BiotherapeuticsN/AN/AN/AN/AN/ACARACara TherapeuticsN/AN/AN/AN/AN/ASTTKShattuck LabsN/AN/AN/AN/AN/ATBPHTheravance BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A3.883.88ARQTArcutis Biotherapeutics0.773.203.04CARACara TherapeuticsN/A4.774.71STTKShattuck LabsN/A10.2510.25TBPHTheravance BiopharmaN/A6.706.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%ARQTArcutis BiotherapeuticsN/ACARACara Therapeutics44.66%STTKShattuck Labs58.74%TBPHTheravance Biopharma99.10%Insider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics5.60%ARQTArcutis Biotherapeutics9.40%CARACara Therapeutics3.10%STTKShattuck Labs12.00%TBPHTheravance Biopharma6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics100108.33 million102.27 millionOptionableARQTArcutis Biotherapeutics150119.90 million108.63 millionOptionableCARACara Therapeutics804.57 million4.43 millionOptionableSTTKShattuck Labs10047.90 million42.16 millionOptionableTBPHTheravance Biopharma11050.36 million46.89 millionOptionableACRS, CARA, ARQT, TBPH, and STTK HeadlinesRecent News About These CompaniesTheravance Biopharma (NASDAQ:TBPH) Stock Crosses Above Fifty Day Moving Average - Here's WhyOctober 17 at 5:11 AM | marketbeat.comTheravance Biopharma Launches Disease Education Campaign to Advance Scientific Understanding of Neurogenic Orthostatic Hypotension Due to Multiple System AtrophyOctober 16 at 8:05 AM | businesswire.comTheravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual MeetingOctober 14 at 6:00 AM | prnewswire.comAnalysts Set Theravance Biopharma, Inc. (NASDAQ:TBPH) PT at $23.00October 12, 2025 | americanbankingnews.comTheravance Biopharma (NASDAQ:TBPH) Earns "Hold (C)" Rating from Weiss RatingsOctober 9, 2025 | marketbeat.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Receives Consensus Recommendation of "Buy" from AnalystsOctober 7, 2025 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Sets New 12-Month High - Time to Buy?October 6, 2025 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Reaches New 12-Month High - Here's What HappenedSeptember 29, 2025 | marketbeat.comAssenagon Asset Management S.A. Takes $264,000 Position in Theravance Biopharma, Inc. $TBPHSeptember 29, 2025 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Downgraded to "Hold" Rating by Zacks ResearchSeptember 18, 2025 | marketbeat.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Sees Significant Increase in Short InterestSeptember 18, 2025 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Reaches New 1-Year High - Here's WhySeptember 17, 2025 | marketbeat.comAcadian Asset Management LLC Buys 174,451 Shares of Theravance Biopharma, Inc. $TBPHSeptember 17, 2025 | marketbeat.comB. Riley Securities Initiates Coverage of Theravance Biopharma (TBPH) with Buy RecommendationSeptember 12, 2025 | msn.comTheravance Biopharma initiated with a Buy at B. RileySeptember 12, 2025 | msn.comTheravance Bio (TBPH) Up 9.8% Since Last Earnings Report: Can It Continue?September 11, 2025 | zacks.comTheravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2, 2025 | prnewswire.comTheravance Biopharma, Inc.: Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic ...August 25, 2025 | finanznachrichten.deTheravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple ...August 25, 2025 | finance.yahoo.comTheravance Biopharma completes enrollment in CYPRESS studyAugust 25, 2025 | msn.comTheravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System AtrophyAugust 25, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACRS, CARA, ARQT, TBPH, and STTK Company DescriptionsAclaris Therapeutics NASDAQ:ACRS$1.90 -0.15 (-7.32%) Closing price 04:00 PM EasternExtended Trading$1.92 +0.02 (+0.79%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Arcutis Biotherapeutics NASDAQ:ARQT$20.88 -0.03 (-0.14%) Closing price 04:00 PM EasternExtended Trading$20.91 +0.03 (+0.14%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Cara Therapeutics NASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Shattuck Labs NASDAQ:STTK$1.81 +0.01 (+0.56%) Closing price 04:00 PM EasternExtended Trading$1.79 -0.02 (-1.10%) As of 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.Theravance Biopharma NASDAQ:TBPH$14.26 +0.22 (+1.57%) Closing price 04:00 PM EasternExtended Trading$14.26 +0.01 (+0.04%) As of 04:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up This Less-Hyped Tech Stock Could Be the Key to the Next AI Wave Archer Buys Rival's Patent Treasure Trove in Strategic Move Prologis Stock Surges: Why the Rally May Continue Intel's Turnaround Hits Hyperspeed With A New 52-Week High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
